NCT00694200

Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Patients With Metastatic Breast Cancer. A Multicenter Phase II Study

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Hellenic Oncology Research Group · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of metronomic oral vinorelbine taken three times a week without break plus bevacizumab as salvage treatment in patients with metastatic breast cancer.

Detailed description

Continuous administration of oral vinorelbine, given three times a week (metronomic) is feasible and exceptionally well tolerated at doses up to 50 mg. Early results show activity against refractory tumors and provide evidence towards clinical proof of efficacy for metronomic chemotherapy. Recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Vinorelbine	Vinorelbine per os 50 mg 3 times a week
DRUG	Bevacizumab	Bevacizumab 10 mg/kg IV every 14 days

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2008-06-10
• Last updated: 2015-05-29

Locations

9 sites across 1 country: Greece